{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:51:31Z","timestamp":1791568291167,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04963-0","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:53:09Z","timestamp":1791521589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond gastric acid: pharmacologic modulation of the tumor microenvironment by vonoprazan and its drug-interaction implications for chemotherapy and immunotherapy"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6100-3182","authenticated-orcid":false,"given":"Ghassan","family":"Sonji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-4763","authenticated-orcid":false,"given":"Nada","family":"Sonji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1756-5298","authenticated-orcid":false,"given":"Afaf","family":"El Katerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"4963_CR1","first-page":"693","volume":"18","author":"N Wong","year":"2022","unstructured":"Wong N, Reddy A, Patel A (2022) Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. Gastroenterol Hepatol (N Y) 18:693\u2013700","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"4963_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41586-018-0003-8","volume":"556","author":"K Abe","year":"2018","unstructured":"Abe K, Irie K, Nakanishi H et al (2018) Crystal structures of the gastric proton pump. Nature 556:214\u2013218. https:\/\/doi.org\/10.1038\/s41586-018-0003-8","journal-title":"Nature"},{"key":"4963_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","volume":"55","author":"H Echizen","year":"2016","unstructured":"Echizen H (2016) The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clin Pharmacokinet 55:409\u2013418. https:\/\/doi.org\/10.1007\/s40262-015-0326-7","journal-title":"Clin Pharmacokinet"},{"key":"4963_CR4","doi-asserted-by":"publisher","first-page":"1269125","DOI":"10.3389\/fphar.2023.1269125","volume":"14","author":"M-L Ouyang","year":"2023","unstructured":"Ouyang M-L, Zou S-P, Cheng Q et al (2023) Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis. Front Pharmacol 14:1269125. https:\/\/doi.org\/10.3389\/fphar.2023.1269125","journal-title":"Front Pharmacol"},{"key":"4963_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2217\/14796694.1.6.779","volume":"1","author":"A De Milito","year":"2005","unstructured":"De Milito A, Fais S (2005) Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 1:779\u2013786. https:\/\/doi.org\/10.2217\/14796694.1.6.779","journal-title":"Future Oncol"},{"key":"4963_CR6","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/jnci\/djh305","volume":"96","author":"F Luciani","year":"2004","unstructured":"Luciani F, Spada M, De Milito A et al (2004) Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs. JNCI J Natl Cancer Inst 96:1702\u20131713. https:\/\/doi.org\/10.1093\/jnci\/djh305","journal-title":"JNCI J Natl Cancer Inst"},{"key":"4963_CR7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.3390\/cancers14102395","volume":"14","author":"S Matsumura","year":"2022","unstructured":"Matsumura S, Ishikawa T, Yoshida J et al (2022) Proton Pump Inhibitors Enhance the Antitumor Effect of Chemotherapy for Esophageal Squamous Cell Carcinoma. Cancers (Basel) 14:2395. https:\/\/doi.org\/10.3390\/cancers14102395","journal-title":"Cancers (Basel)"},{"key":"4963_CR8","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","volume":"72","author":"A Calcinotto","year":"2012","unstructured":"Calcinotto A, Filipazzi P, Grioni M et al (2012) Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Res 72:2746\u20132756. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1272","journal-title":"Cancer Res"},{"key":"4963_CR9","doi-asserted-by":"publisher","first-page":"e70260","DOI":"10.1111\/apha.70260","volume":"242","author":"FB Christiansen","year":"2026","unstructured":"Christiansen FB, Novella ES, Lindemann AV et al (2026) T Cell Dysfunction in the Acidic Tumor Microenvironment. Acta Physiol 242:e70260. https:\/\/doi.org\/10.1111\/apha.70260","journal-title":"Acta Physiol"},{"key":"4963_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","volume":"76","author":"S Pilon-Thomas","year":"2016","unstructured":"Pilon-Thomas S, Kodumudi KN, El-Kenawi AE et al (2016) Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res 76:1381\u20131390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1743","journal-title":"Cancer Res"},{"key":"4963_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13046-015-0194-x","volume":"34","author":"B-Y Wang","year":"2015","unstructured":"Wang B-Y, Zhang J, Wang J-L et al (2015) Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 34:85. https:\/\/doi.org\/10.1186\/s13046-015-0194-x","journal-title":"J Exp Clin Cancer Res"},{"key":"4963_CR12","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/jcb.24122","volume":"113","author":"M Chen","year":"2012","unstructured":"Chen M, Huang S, Zhang X et al (2012) Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V\u2010ATPases\/mTOR\/HIF\u20101\u03b1\/P\u2010gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 113:2474\u20132487. https:\/\/doi.org\/10.1002\/jcb.24122","journal-title":"J Cell Biochem"},{"key":"4963_CR13","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.3748\/wjg.v25.i17.2058","volume":"25","author":"MK Joo","year":"2019","unstructured":"Joo MK, Park J-J, Chun HJ (2019) Proton pump inhibitor: The dual role in gastric cancer. World J Gastroenterol 25:2058\u20132070. https:\/\/doi.org\/10.3748\/wjg.v25.i17.2058","journal-title":"World J Gastroenterol"},{"key":"4963_CR14","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/cancers17132228","volume":"17","author":"G Ciappina","year":"2025","unstructured":"Ciappina G, Ottaiano A, Santorsola M et al (2025) Impact of Proton Pump Inhibitor Use on Progression-Free and Overall Survival in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis of Recent Studies. Cancers 17:2228. https:\/\/doi.org\/10.3390\/cancers17132228","journal-title":"Cancers"},{"key":"4963_CR15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M et al (2016) Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65:1439\u20131446. https:\/\/doi.org\/10.1136\/gutjnl-2015-311304","journal-title":"Gut"},{"key":"4963_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.20524\/aog.2025.0966","volume":"38","author":"M Shatila","year":"2025","unstructured":"Shatila M, Sperling G, Machado AP et al (2025) Helicobacter pylori infection negatively affects response of gastric cancer to immunotherapy. Ann Gastroenterol 38:262\u2013269. https:\/\/doi.org\/10.20524\/aog.2025.0966","journal-title":"Ann Gastroenterol"},{"key":"4963_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J et al (2010) 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases. J Pharmacol Exp Ther 335:231\u2013238. https:\/\/doi.org\/10.1124\/jpet.110.170274","journal-title":"J Pharmacol Exp Ther"},{"key":"4963_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1586\/ecp.09.33","volume":"2","author":"JM Shin","year":"2009","unstructured":"Shin JM, Sachs G (2009) Long-lasting inhibitors of the gastric H,K-ATPase. Expert Rev Clin Pharmacol 2:461\u2013468. https:\/\/doi.org\/10.1586\/ecp.09.33","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4963_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-9966-29-44","volume":"29","author":"EP Spugnini","year":"2010","unstructured":"Spugnini EP, Citro G, Fais S (2010) Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res 29:44. https:\/\/doi.org\/10.1186\/1756-9966-29-44","journal-title":"J Exp Clin Cancer Res"},{"key":"4963_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1080\/13880209.2023.2173253","volume":"61","author":"S Zhou","year":"2023","unstructured":"Zhou S, Zhao F-L, Wang S-H et al (2023) Assessments of CYP\u2013inhibition\u2013based drug\u2013drug interaction between vonoprazan and poziotinib in vitro and in vivo. Pharm Biol 61:356\u2013361. https:\/\/doi.org\/10.1080\/13880209.2023.2173253","journal-title":"Pharm Biol"},{"key":"4963_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ddr.22013","volume":"84","author":"R Ando-Matsuoka","year":"2023","unstructured":"Ando-Matsuoka R, Yagi K, Takaoka M et al (2023) Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells. Drug Dev Res 84:75\u201383. https:\/\/doi.org\/10.1002\/ddr.22013","journal-title":"Drug Dev Res"},{"key":"4963_CR22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2024.08.004","volume":"23","author":"N Uemura","year":"2025","unstructured":"Uemura N, Kinoshita Y, Haruma K et al (2025) Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study. Clin Gastroenterol Hepatol 23:748\u2013757e5. https:\/\/doi.org\/10.1016\/j.cgh.2024.08.004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4963_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/gutjnl-2023-330883","volume":"73","author":"X Xiao","year":"2024","unstructured":"Xiao X, Zhang X, Wang J et al (2024) Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study. Gut 73:1098\u20131109. https:\/\/doi.org\/10.1136\/gutjnl-2023-330883","journal-title":"Gut"},{"key":"4963_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L et al (2018) Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science 359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236","journal-title":"Science"},{"key":"4963_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L et al (2018) Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science 359:91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706","journal-title":"Science"},{"key":"4963_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy. Science 350:1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"key":"4963_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc.2017.77","volume":"17","author":"C Corbet","year":"2017","unstructured":"Corbet C, Feron O (2017) Tumour acidosis: from the passenger to the driver\u2019s seat. Nat Rev Cancer 17:577\u2013593. https:\/\/doi.org\/10.1038\/nrc.2017.77","journal-title":"Nat Rev Cancer"},{"key":"4963_CR28","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/0008-5472.CAN-12-2796","volume":"73","author":"V Estrella","year":"2013","unstructured":"Estrella V, Chen T, Lloyd M et al (2013) Acidity Generated by the Tumor Microenvironment Drives Local Invasion. Cancer Res 73:1524\u20131535. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2796","journal-title":"Cancer Res"},{"key":"4963_CR29","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3390\/cells13221924","volume":"13","author":"MA Rahman","year":"2024","unstructured":"Rahman MA, Yadab MK, Ali MM (2024) Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy. Cells 13:1924. https:\/\/doi.org\/10.3390\/cells13221924","journal-title":"Cells"},{"key":"4963_CR30","doi-asserted-by":"publisher","first-page":"3119375","DOI":"10.1155\/2022\/3119375","volume":"2022","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhou H, Liu G et al (2022) Tumor Microenvironment: Lactic Acid Promotes Tumor Development. J Immunol Res 2022:3119375. https:\/\/doi.org\/10.1155\/2022\/3119375","journal-title":"J Immunol Res"},{"key":"4963_CR31","doi-asserted-by":"publisher","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","volume":"16","author":"X-Y Gu","year":"2025","unstructured":"Gu X-Y, Yang J-L, Lai R et al (2025) Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol 16:1563303. https:\/\/doi.org\/10.3389\/fimmu.2025.1563303","journal-title":"Front Immunol"},{"key":"4963_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3892\/mmr.2024.13413","volume":"31","author":"Y Zeng","year":"2025","unstructured":"Zeng Y, Huang Y, Tan Q et al (2025) Influence of lactate in resistance to anti\u2013PD\u20131\/PD\u2013L1 therapy: Mechanisms and clinical applications (Review). Mol Med Rep 31:48. https:\/\/doi.org\/10.3892\/mmr.2024.13413","journal-title":"Mol Med Rep"},{"key":"4963_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ctrv.2009.08.003","volume":"35","author":"M P\u00e9rez-Say\u00e1ns","year":"2009","unstructured":"P\u00e9rez-Say\u00e1ns M, Somoza-Mart\u00edn JM, Barros-Angueira F et al (2009) V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 35:707\u2013713. https:\/\/doi.org\/10.1016\/j.ctrv.2009.08.003","journal-title":"Cancer Treat Rev"},{"key":"4963_CR34","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.3390\/ijms21124392","volume":"21","author":"J Hrab\u011bta","year":"2020","unstructured":"Hrab\u011bta J, Belhajov\u00e1 M, \u0160ubrtov\u00e1 H et al (2020) Drug Sequestration in Lysosomes as One of the Mechanisms of Chemoresistance of Cancer Cells and the Possibilities of Its Inhibition. IJMS 21:4392. https:\/\/doi.org\/10.3390\/ijms21124392","journal-title":"IJMS"},{"key":"4963_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.20517\/cdr.2021.134","volume":"5","author":"T Koltai","year":"2022","unstructured":"Koltai T (2022) The complex relationship between multiple drug resistance and the tumor pH gradient: a review. Cancer Drug Resist 5:277\u2013303. https:\/\/doi.org\/10.20517\/cdr.2021.134","journal-title":"Cancer Drug Resist"},{"key":"4963_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","volume":"24","author":"B Zhitomirsky","year":"2016","unstructured":"Zhitomirsky B, Assaraf YG (2016) Lysosomes as mediators of drug resistance in cancer. Drug Resist Updates 24:23\u201333. https:\/\/doi.org\/10.1016\/j.drup.2015.11.004","journal-title":"Drug Resist Updates"},{"key":"4963_CR37","doi-asserted-by":"publisher","first-page":"e88193","DOI":"10.1371\/journal.pone.0088193","volume":"9","author":"C Federici","year":"2014","unstructured":"Federici C, Petrucci F, Caimi S et al (2014) Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin. PLoS ONE 9:e88193. https:\/\/doi.org\/10.1371\/journal.pone.0088193","journal-title":"PLoS ONE"},{"key":"4963_CR38","doi-asserted-by":"publisher","first-page":"743556","DOI":"10.3389\/fonc.2021.743556","volume":"11","author":"Y Zhong","year":"2021","unstructured":"Zhong Y, Li H, Li P et al (2021) Exosomes: A New Pathway for Cancer Drug Resistance. Front Oncol 11:743556. https:\/\/doi.org\/10.3389\/fonc.2021.743556","journal-title":"Front Oncol"},{"key":"4963_CR39","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s10238-023-01008-1","volume":"23","author":"K Yagi","year":"2023","unstructured":"Yagi K, Maruo A, Ishida S et al (2023) Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study. Clin Exp Med 23:2799\u20132804. https:\/\/doi.org\/10.1007\/s10238-023-01008-1","journal-title":"Clin Exp Med"},{"key":"4963_CR40","doi-asserted-by":"publisher","first-page":"204209862412602","DOI":"10.1177\/20420986241260211","volume":"15","author":"M Ouyang","year":"2024","unstructured":"Ouyang M, Zou S, Cheng Q et al (2024) Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System. Therapeutic Adv Drug Saf 15:20420986241260211. https:\/\/doi.org\/10.1177\/20420986241260211","journal-title":"Therapeutic Adv Drug Saf"},{"key":"4963_CR41","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1136\/gutjnl-2016-313312","volume":"66","author":"T Otsuka","year":"2017","unstructured":"Otsuka T, Sugimoto M, Inoue R et al (2017) Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori -negative healthy individuals. Gut 66:1723\u20131725. https:\/\/doi.org\/10.1136\/gutjnl-2016-313312","journal-title":"Gut"},{"key":"4963_CR42","doi-asserted-by":"publisher","first-page":"1512683","DOI":"10.3389\/fimmu.2024.1512683","volume":"15","author":"MY Lim","year":"2025","unstructured":"Lim MY, Hong S, Nam Y-D (2025) Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: a review. Front Immunol 15:1512683. https:\/\/doi.org\/10.3389\/fimmu.2024.1512683","journal-title":"Front Immunol"},{"key":"4963_CR43","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu M, Riester Z, Baldrich A et al (2021) Microbial short-chain fatty acids modulate CD8\u2009+\u2009T cell responses and improve adoptive immunotherapy for cancer. Nat Commun 12:4077. https:\/\/doi.org\/10.1038\/s41467-021-24331-1","journal-title":"Nat Commun"},{"key":"4963_CR44","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1007\/s10147-025-02805-2","volume":"30","author":"M Takahashi","year":"2025","unstructured":"Takahashi M, Nakatsukasa H, Shibano M et al (2025) Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors. Int J Clin Oncol 30:1582\u20131592. https:\/\/doi.org\/10.1007\/s10147-025-02805-2","journal-title":"Int J Clin Oncol"},{"key":"4963_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR et al (2020) Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 31:525\u2013531. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.006","journal-title":"Ann Oncol"},{"key":"4963_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","volume":"126","author":"AM Hopkins","year":"2022","unstructured":"Hopkins AM, Kichenadasse G, McKinnon RA et al (2022) Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 126:42\u201347. https:\/\/doi.org\/10.1038\/s41416-021-01606-4","journal-title":"Br J Cancer"},{"key":"4963_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10147-025-02922-y","volume":"31","author":"M Takahashi","year":"2026","unstructured":"Takahashi M, Takahashi K, Uchida-Kobayashi S et al (2026) Effect of Vonoprazan, potassium-competitive acid blocker, on Atezolizumab plus Bevacizumab efficacy in patients with hepatocellular carcinoma: a multicenter retrospective study. Int J Clin Oncol 31:141\u2013150. https:\/\/doi.org\/10.1007\/s10147-025-02922-y","journal-title":"Int J Clin Oncol"},{"key":"4963_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-026-02469-3","author":"K Mizuno","year":"2026","unstructured":"Mizuno K, Chretien B, Nishida K et al (2026) Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study. J Gastroenterol. https:\/\/doi.org\/10.1007\/s00535-026-02469-3","journal-title":"J Gastroenterol"},{"key":"4963_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2169\/internalmedicine.2521-18","volume":"59","author":"S Kiyotoki","year":"2020","unstructured":"Kiyotoki S, Nishikawa J, Sakaida I (2020) Efficacy of Vonoprazan for Helicobacter pylori Eradication. Intern Med 59:153\u2013161. https:\/\/doi.org\/10.2169\/internalmedicine.2521-18","journal-title":"Intern Med"},{"key":"4963_CR50","doi-asserted-by":"publisher","first-page":"104760","DOI":"10.1016\/j.amsu.2022.104760","volume":"82","author":"M Shehryar","year":"2022","unstructured":"Shehryar M, Ahmad RU, Kareem HK et al (2022) Efficacy, safety and cost-effectiveness of vonoprazan vs Proton Pump Inhibitors in reflux disorders and H. pylori eradication: A literature review. Ann Med Surg (Lond) 82:104760. https:\/\/doi.org\/10.1016\/j.amsu.2022.104760","journal-title":"Ann Med Surg (Lond)"},{"key":"4963_CR51","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMsb2515372","volume":"394","author":"JY Park","year":"2026","unstructured":"Park JY, Lee Y-C, Moayyedi P et al (2026) Helicobacter pylori Screen-and-Treat Programs for Gastric Cancer Prevention \u2014 IARC Working Group Report. N Engl J Med 394:1131\u20131137. https:\/\/doi.org\/10.1056\/NEJMsb2515372","journal-title":"N Engl J Med"},{"key":"4963_CR52","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cgh.2024.01.037","volume":"22","author":"J Arai","year":"2024","unstructured":"Arai J, Miyawaki A, Aoki T et al (2024) Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication. Clin Gastroenterol Hepatol 22:1217\u20131225e6. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.037","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4963_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"KS Cheung","year":"2018","unstructured":"Cheung KS, Chan EW, Wong AYS et al (2018) Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 67:28\u201335. https:\/\/doi.org\/10.1136\/gutjnl-2017-314605","journal-title":"Gut"},{"key":"4963_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12876-023-02772-w","volume":"23","author":"K Haruma","year":"2023","unstructured":"Haruma K, Kinoshita Y, Yao T et al (2023) Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis. BMC Gastroenterol 23:139. https:\/\/doi.org\/10.1186\/s12876-023-02772-w","journal-title":"BMC Gastroenterol"},{"key":"4963_CR55","doi-asserted-by":"publisher","first-page":"1798103","DOI":"10.3389\/fphar.2026.1798103","volume":"17","author":"FN Alenezi","year":"2026","unstructured":"Alenezi FN, Abdelmageed ME, Nader MA, Zaghloul MS (2026) Vonoprazan as an adjuvant to cisplatin: enhancing antitumor efficacy while mitigating nephrotoxicity and gastrointestinal adverse effects. Front Pharmacol 17:1798103. https:\/\/doi.org\/10.3389\/fphar.2026.1798103","journal-title":"Front Pharmacol"},{"key":"4963_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"4963_CR57","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"4963_CR58","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"4963_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/IJN.S587953","volume":"21","author":"B Han","year":"2026","unstructured":"Han B, Han Z, Zhang Y (2026) Advances in Nanotechnology for Lymphoma Treatment: Targeted Delivery, Immunomodulation, and TME-Responsive Therapy Strategies. Int J Nanomed Volume 21:1\u201329. https:\/\/doi.org\/10.2147\/IJN.S587953","journal-title":"Int J Nanomed Volume"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04963-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04963-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:03:10Z","timestamp":1791565390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04963-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4963"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04963-0","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative review and did not involve primary research with human participants or animals.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate\/Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}